KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer

Porta, Camillo; Bamias, Aristotelis; Danesh, Farhad R.; Dębska‐Ślizień, Alicja; Gallieni, Maurizio; Gertz, Morie A.; Kielstein, Jan T.; Tesařová, Petra; Wong, Germaine; Cheung, Michael; Wheeler, David C.; Winkelmayer, Wolfgang C.; Małyszko, Jolanta; Abu‐Alfa, Ali K.; Amer, Hatem; Beutel, Gernot; Chapman, Jeremy R.; Chen, Xiaohong; Chudek, Jerzy; Cosmai, Laura; Danesi, Romano; Stefano, Filippo De; Iseki, Kunitoshi; Jaimes, Edgar A.; Jhaveri, Kenar D.; Jurczyszyn, Artur; Kazancıoğlu, Rümeyza; Kitchlu, Abhijat; Kollmannsberger, Christian; Lahoti, Amit; Yang, Li; Macía, Manuel; Matsubara, Takeshi; Mitropoulos, Dionysios; Noiri, Eisei; Perazella, Mark A.; Ronco, Pierre; Rosner, Mitchell H.; Romeo, María José Soler; Sprangers, Ben; Stadler, Walter M.; Stevens, Paul E.; Tesař, ladimír; Silva, Verônica Torres da Costa e; Vijayan, Anitha; Viklický, Ondřej; Workeneh, Biruh; Yanagita, Motoko; Zakharova, Elena

doi:10.1016/j.kint.2020.06.046

Cited by 31 publications

(19 citation statements)

References 108 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hence, an international working group for imaging of cystic kidney disease has recommended yearly follow-up of children on dialysis with ultrasound for ACKD [ 23 ]. In 2020, KDIGO nephron-oncology controversy conference has highlighted to prioritize the research areas like cost and tools of screening for malignancy in CKD and establish the causal effect of ACKD and RCC [ 24 ].…”

Section: Discussionmentioning

confidence: 99%

Acquired Cystic Kidney Disease: A Hidden Complication in Children on Chronic Hemodialysis

Khatri¹,

Bajeer²,

Lanewala³

et al. 2022

Cureus

View full text Add to dashboard Cite

Objective To determine the frequency of acquired cystic kidney disease (ACKD) in children on chronic hemodialysis. Material and methods In this single-center cross-sectional study, 150 children were included who were on chronic hemodialysis for six months. Ultrasound was done to see the renal cysts. Cystic changes that could not fulfill the criteria for ACKD were also noted and analyzed. Results The mean age was 14.5 ± 3.5 years, of these 63 (42%) were males. Acquired cysts were detected in 53 (35%) of the patient and 18 patients (12%) had solitary cysts. The distribution of these entities was similar across all age groups. The underlying etiologies in the descending order were unknown 64 (43%), stone disease 31 (21%), each of the congenital anomalies of the kidney and urinary tract, and glomerulonephritis 23 (15%), and others nine (6%). A higher frequency of ACKD was detected in the children on renal replacement therapy for more than two years (33 out of 53 children, 63% with a p-value of 0.004). Conclusion The ACKD was found in one-third of our hemodialysis children and its frequency increases with the duration of hemodialysis. This percentage may not reflect the true prevalence as there is a lack of consensus on the definition of ACKD. Periodic assessment of chronic kidney disease patients for the development of ACKD especially on chronic hemodialysis is required to reduce the morbidity.

show abstract

Section: Discussionmentioning

confidence: 99%

Acquired Cystic Kidney Disease: A Hidden Complication in Children on Chronic Hemodialysis

Khatri¹,

Bajeer²,

Lanewala³

et al. 2022

Cureus

View full text Add to dashboard Cite

show abstract

“…The best management strategies to counteract such toxicity are largely unknown. Renal monitoring is crucial for patients who receive these treatments, both before initiation and also during therapy, to identify renal adverse events [160]. French recommendations for good practice have been published, emphasizing the need for multidisciplinary coordination in the follow-up of these patients [184].…”

Section: Discussionmentioning

confidence: 99%

“…Cancer patients are at risk for acute kidney injury, with a high prevalence of chronic kidney disease [158][159][160]. Kidney vulnerability to various nephrotoxic agents can be attributed to several functional properties.…”

Section: Kidney Dysfunctionmentioning

confidence: 99%

“…Creating a database registry for anti-angiogenic therapies and their renal adverse effects could be very helpful [169]. In the KDIGO (Kidney Disease Improving Global Outcomes) Controversies Conference on onco-nephrology, for patients with CKD, TKIs may be used at a lower-than-standard dose and increased secondarily according to individual tolerability and response [160].…”

Section: Kidney Dysfunctionmentioning

confidence: 99%

See 1 more Smart Citation

Nephrotoxicity of Anti-Angiogenic Therapies

et al. 2021

View full text Add to dashboard Cite

The use of inhibitors of vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor 2 (VEGFR2) signaling for the treatment of cancer has increased over the last decade. This signaling pathway plays a fundamental role in angiogenesis and also in kidney physiology. The emergence of anti-angiogenic therapies has led to adverse nephrotoxic effects, despite improving the outcomes of patients. In this review, we will present the different anti-angiogenic therapies targeting the VEGFR pathway in association with the incidence of renal manifestations during their use. In addition, we will discuss, in detail, the pathophysiological mechanisms of frequent renal diseases such as hypertension, proteinuria, renal dysfunction, and electrolyte disorders. Finally, we will outline the cellular damage described following these therapies.

show abstract

“…Therapies maximizing nephron-sparing is a priority for RCC patients in whom the prevalence of CKD is high ( 36 ). More efficacious and safer SBRT can be achieved with dose escalation and a reduction in margins, and requires MRgRT systems to advance with enhanced MRI sequences, intrafraction tracking and gating, and treatment adaptation.…”

Section: Future Opportunitiesmentioning

confidence: 99%

Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma

et al. 2021

View full text Add to dashboard Cite

Adaptive MR-guided radiotherapy (MRgRT) is a new treatment paradigm and its role as a non-invasive treatment option for renal cell carcinoma is evolving. The early clinical experience to date shows that real-time plan adaptation based on the daily MRI anatomy can lead to improved target coverage and normal tissue sparing. Continued technological innovations will further mitigate the challenges of organ motion and enable more advanced treatment adaptation, and potentially lead to enhanced oncologic outcomes and preservation of renal function. Future applications look promising to make a positive clinical impact and further the personalization of radiotherapy in the management of renal cell carcinoma.

show abstract

KDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancer

Cited by 31 publications

References 108 publications

Acquired Cystic Kidney Disease: A Hidden Complication in Children on Chronic Hemodialysis

Acquired Cystic Kidney Disease: A Hidden Complication in Children on Chronic Hemodialysis

Nephrotoxicity of Anti-Angiogenic Therapies

Adaptive Magnetic Resonance-Guided Stereotactic Body Radiotherapy: The Next Step in the Treatment of Renal Cell Carcinoma

Contact Info

Product

Resources

About